Review




Structured Review

SignaGen lipod293 transfection reagent
Lipod293 Transfection Reagent, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pmc11287164__pnas__2303642121__sapp-9-0-5
Average 90 stars, based on 1 article reviews
lipod293 transfection reagent - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

shRNA:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Plasmid Preparation:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Transfection:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Control:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Purification:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Recombinant:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Red Blood Cell Lysis:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Activation Assay:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Membrane:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Staining:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Isolation:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

DC Protein Assay:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Enzyme-linked Immunosorbent Assay:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Expressing:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Amplification:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Software:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Imaging:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Spectrophotometry:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Lysis:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Protease Inhibitor:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Western Blot:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

SYBR Green Assay:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Produced:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Positive Control:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Cell Culture:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Modification:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).

Construct:

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: Cells were either transfected with 1 μg of LRRK2 constructs, co-transfected with 1 μg of LRRK2 and 100 ng RL1d-GFP construct, or co-transfected with 1 μg of pCMV and 100 ng of GFP-RILPL1, RILPL1-GFP or RILPL1-miniSOG constructs, along with 4 μl of LipoD293TM Transfection Reagent (SignaGen Laboratories) per well of a 12-well plate.

Article Title: LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages
Article Snippet: A549 cells were cultured in glass-bottom MatTek dishes (MatTek Life Sciences, P35G-0-14-C) and transfected with RILPL1-miniSOG-HA using LipoD293TM Transfection Reagent (SignaGen Laboratories, SL100668) as described above.

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293TM Transfection Reagent (SignaGen Laboratories).

Article Title: Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models
Article Snippet: Lentivirus containing supernatants were produced in packaging (293T) cells transfected with individual elF4B shRNAs or the pLKO.1 eGFP positive control using LipoD293TM transfection reagent (SignaGen Laboratories; Cat# SL100668) at a 1:2.5 DNA:Lipo ratio (2.5ug transfer plasmid + 2.5ug psPAX2 + 1.0ug pMD2.G and 15ul lipoD per plate).



Similar Products

90
SignaGen lipod293 transfection reagent
Lipod293 Transfection Reagent, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pmc11287164__pnas__2303642121__sapp-9-0-5
Average 90 stars, based on 1 article reviews
lipod293 transfection reagent - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
SignaGen lipod293 dna transfection reagent
Lipod293 Dna Transfection Reagent, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pm40210047-79-5-12
Average 90 stars, based on 1 article reviews
lipod293 dna transfection reagent - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
SignaGen transfection reagent lipod293
Transfection Reagent Lipod293, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pm39814716-316-6-9
Average 90 stars, based on 1 article reviews
transfection reagent lipod293 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
SignaGen lipod293 in vitro dna transfection reagent
Lipod293 In Vitro Dna Transfection Reagent, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pmc11919155-104-5-11
Average 90 stars, based on 1 article reviews
lipod293 in vitro dna transfection reagent - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
SignaGen lipod293™ transfection reagent
Reagents and tools table
Lipod293™ Transfection Reagent, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pmc11772817-431-24-27
Average 90 stars, based on 1 article reviews
lipod293™ transfection reagent - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
SignaGen lipod293 vitro dna transfection reagent
Reagents and tools table
Lipod293 Vitro Dna Transfection Reagent, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lipod293%E2%84%A2+transfection+reagent/lipod293/pm39655935-354-49-56
Average 90 stars, based on 1 article reviews
lipod293 vitro dna transfection reagent - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Reagents and tools table

Journal: EMBO Reports

Article Title: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors

doi: 10.1038/s44319-024-00333-0

Figure Lengend Snippet: Reagents and tools table

Article Snippet: To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293™ Transfection Reagent (SignaGen Laboratories).

Techniques: Control, Purification, Recombinant, Red Blood Cell Lysis, Activation Assay, Membrane, Staining, Isolation, Plasmid Preparation, DC Protein Assay, Enzyme-linked Immunosorbent Assay, Expressing, shRNA, Amplification, Software, Imaging, Spectrophotometry, Lysis, Protease Inhibitor, Western Blot, SYBR Green Assay, Transfection